By Elaine Sanchez
Brooke Army Medical Center at Joint Base San Antonio-Fort Sam Houston, Texas, is expanding its use of a highly specialized treatment for critically ill COVID-19 patients.
Extracorporeal membrane oxygenation, or ECMO, is a heart-lung bypass intervention that is proving to be lifesaving for some COVID-19 patients.
"ECMO is often the last line of defense for the most critically ill patients with severe pulmonary disease," said Air Force Col. (Dr.) Patrick Osborn, BAMC's deputy commander for surgical services. "Whether due to COVID-19 or another condition, ECMO provides a life-support option that can potentially save lives when all other options are exhausted."
BAMC, one of the few local facilities that offer the treatment, is providing up to one-third of the ECMO capability for the San Antonio area's most severely ill residents, veterans and military beneficiaries suffering from the virus.
"ECMO is not a treatment for any specific disease," said Air Force Col. (Dr.) Phillip Mason, medical director for BAMC's adult ECMO program. "It works by keeping critically ill patients alive and buying time for us to address their underlying condition. In some cases, we can reduce a patient's chance of dying from 80 to 90 percent down to 30 to 40 percent. While 30 to 40 percent is still high, it represents a significant improvement and translates into many lives saved."
Established in October 2012, BAMC's adult ECMO center is the only one in the Defense Department, and it remains one of the few centers with global air transportable ECMO capability. The multiservice ECMO team has traveled as far as Iraq and Afghanistan to pick up service members in need of the treatment.
An ECMO team carefully considers the treatment after other lifesaving measures, such as oxygen therapy or a ventilator, have proven ineffective.
"The vast majority of the critical care community believes that ECMO is effective as a rescue therapy for respiratory failure that does not respond to conventional therapies," Mason noted.
BAMC is also part of a multinational observational trial of ECMO's use for COVID-19. The trial should help to reveal evidence-based proof of the treatment’s effectiveness, but that's further down the line, Mason said.
"While COVID is a complex disease affecting many organ systems, its primary manifestation is respiratory failure, so there is at least some reason to believe ECMO will be effective," he said, noting the treatment is often used for other viral respiratory illnesses, such as influenza.
With the program in place for nearly a decade, BAMC's COVID-19 team is accustomed to working closely with local hospitals in the event a patient may be a candidate for ECMO. This collaboration has stepped up in recent months, creating a larger influx of patients.
To expand capacity to meet the growing community need, BAMC called on its ECMO team to train additional nurses and technicians on the equipment, while also leaning on personnel from the U.S. Army Institute of Surgical Research Burn Center, which is housed in the hospital, to assist.